Analysis of molecular markers in glioblastoma and correlation with survival pattern

Abstract

Objective: The objective of this study was to apply the newly recommended mandatory immunohistochemical
(IHC) markers, isocitrate dehydrogenase (IDH) and ATRX, in addition to our previously applied panel of
p53, epidermal growth factor receptor [EGFR], vascular endothelial growth factor [VEGF], MDM2, and Ki67
on histopathologically diagnosed thirty cases of glioblastoma. Their interrelationship and correlation with
survival pattern were analyzed.
Materials and Methods: A retrospective analysis of the histopathology records and clinical case files was
done in thirty cases of glioblastoma (World Health Organization Grade IV). These cases were analyzed for
certain defined clinical and histopathological parameters. IHC staining for IDH1‐R132H and ATRX was done.
IHC scores for p53, EGFR, VEGF, MDM2, and Ki67 were included from the previously published dataset.
IHC labeling of all these markers was analyzed, and their interrelationship was studied and correlated with
the survival pattern.
Results: Cases were categorized as glioblastoma, IDH‐wild type; glioblastoma, IDH‐mutant; and glioblastoma,
not otherwise specified (NOS). A total of 17 cases were categorized as glioblastoma, IDH‐wild type and
10 cases were categorized as glioblastoma, IDH‐mutant. Three cases in younger adults were categorized as
glioblastoma, NOS. In glioblastoma, IDH‐wild type, p53 expression was found in 7 cases, increased Ki67
expression was present in 12 cases, VEGF expression was found in 16 cases, MDM2 was expressed in
14 cases, while EGFR expression was present in 10 cases. In glioblastoma, IDH‐mutant, p53 expression was
found in 5 cases, increased Ki67 expression was present in 4 cases, VEGF expression was found in 9 cases,
MDM2 was expressed in 5 cases, while EGFR expression was present in 3 cases. The mean overall survival
in glioblastoma, IDH‐wild type was 3.1 months and, in glioblastoma, IDH‐mutant, the mean overall survival
was 6.4 months.
Conclusion: Survival pattern of glioblastoma, IDH‐mutant, was better than glioblastoma, IDH‐wild type.